
HBV-mediated Suppression of Megakaryocyte Differentiation through UBE4B Upregulation and Modulation of p53 and ERK1/2
简介:
- 作者: Huinan Jiang, Qiuju Sheng, Yanwei Li, Xiaoguang Dou, Yang Ding, Chong Zhang, Chao Han, Yaoxin Fan
- 杂志: Research Square
- Doi: https://www.doi.org/10.21203/rs.3.rs-4121319/v1
- 出版日期: 2024 Apr 2
论文中使用的产品/服务
Quotation shows PackGene:UBE4B knockdown lentivirus (Packgene, Guangzhou)
Research Field:HBV
AAV Serotype:lentivirus
Targeted organ:megakaryocytes
Animal or cell line strain:mice
摘要
Background: Hepatitis B virus (HBV) infection can cause thrombocytopenia through its effects on hematopoiesis, but the mechanisms underlying this process are still unclear. The process of platelet generation encompasses multiple stages, among these stages, the differentiation of mature megakaryocytes plays a pivotal role in platelet production. Objective: In this study, we investigated the impact of HBV on the differentiation of mature megakaryocytes and its molecular mechanism. Methods: Different doses of HBV virus solution extracted from HepAD38 cells were co-cultured with hematopoietic stem cells isolated from fresh, full-term healthy maternal cord blood through magnetic bead sorting. The study aimed to assess the variances in megakaryocyte differentiation and maturation after HBV infection. Furthermore, Label-free quantitative proteomics was employed to analyze the differential proteins during the mature megakaryocyte stages pre- and post-HBV infection, with a focus on elucidating their respective molecular mechanisms. Results: Through comparison, it was discovered that HBV could impede the differentiation process of fully developed megakaryocytes. Specifically, during the maturation stage of megakaryocytes, HBV had the ability to hinder cell DNA polyploidization as well as the formation of cytoskeletal proteins. Furthermore, its suppressive effect was more pronounced in the later stages of differentiation, consequently leading to impaired platelet production. Proteomic analysis revealed noteworthy disparities in UBE4B protein levels within mature megakaryocytes after HBV infection. Upon transfection with lentivirus and subsequent knockdown of UBE4B in mature megakaryocytes, a noticeable alleviation of HBV's inhibitory impact on mature megakaryocytes was observed, accompanied by regulation of p53 and ERK1/2 expression and phosphorylation in the cells. Conclusion: HBV can upregulate the expression of UBE4B, inhibit the expression and phosphorylation of p53, enhance the expression and phosphorylation of ERK1/2, suppress the differentiation of mature megakaryocytes, thereby leading to platelet production disorders.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
